Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dilanubicel - Nohla Therapeutics

Next Previous
Search
Drug Profile

Dilanubicel - Nohla Therapeutics

Alternative Names: Ex vivo expanded universal donor cellular therapies - Nohla Therapeutics; Ex vivo-expanded cord blood progenitor cells; Haematopoetic progenitor cell therapy - Nohla Therapeutics; Haematopoetic-stem-cell-therapy-Nohla-Therapeutics; NLA 101; Notch-mediated ex vivo expanded cord blood HSPC - Nohla Therapeutics

Latest Information Update: 09 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Fred Hutchinson Cancer Research Center; National Cancer Institute (USA); National Heart, Lung and Blood Institute; Nohla Therapeutics
  • Class Antineoplastics; Haematopoietic stem cells therapies; Immunotherapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Neutropenia
  • No development reported Acute radiation syndrome; Graft-versus-host disease; Transplant rejection

Most Recent Events

  • 24 Jan 2024 Nohla Therapeutics reinitiates enrollment a phase II trial in Myelodysplastic syndromes, Chronic myeloid leukaemia, Acute myeloid leukaemia (In adults, In the elderly, Second-line therapy or greater) and Haematological malignancies in USA (IV) (NCT03399773)
  • 10 Jan 2024 Nohla Therapeutics suspends a phase II trial in Myelodysplastic syndromes, Chronic myeloid leukaemia, Acute myeloid leukaemia (In adults, In the elderly, Second-line therapy or greater) and Haematological malignancies in USA (IV) as study met its initial enrollment goal and researchers are modifying study to expand enrollment (NCT03399773)
  • 28 Aug 2022 No recent reports of development identified for preclinical development in Transplant-rejection in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top